BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16258498)

  • 1. Review of fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas.
    Khan N; Oriuchi N; Higuchi T; Endo K
    Cancer Control; 2005 Oct; 12(4):254-60. PubMed ID: 16258498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases.
    Mucha SA; Kunert-Radek J; Pomorski L
    Endokrynol Pol; 2006; 57(4):452-5. PubMed ID: 17006852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
    Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
    Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging.
    Marzola MC; Pelizzo MR; Ferdeghini M; Toniato A; Massaro A; Ambrosini V; Fanti S; Gross MD; Al-Nahhas A; Rubello D
    Eur J Surg Oncol; 2010 Apr; 36(4):414-21. PubMed ID: 20100647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis.
    Treglia G; Villani MF; Giordano A; Rufini V
    Endocrine; 2012 Dec; 42(3):535-45. PubMed ID: 22527889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.
    Naswa N; Sharma P; Suman Kc S; Lata S; Kumar R; Malhotra A; Bal C
    Nucl Med Commun; 2012 Jul; 33(7):766-74. PubMed ID: 22531829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer.
    de Groot JW; Links TP; Jager PL; Kahraman T; Plukker JT
    Ann Surg Oncol; 2004 Aug; 11(8):786-94. PubMed ID: 15289241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer.
    Brandt-Mainz K; Müller SP; Görges R; Saller B; Bockisch A
    Eur J Nucl Med; 2000 May; 27(5):490-6. PubMed ID: 10853802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ¹⁸F-FDG-PET and ¹⁸F-FDG-PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: a systematic review and meta-analysis.
    Cheng X; Bao L; Xu Z; Li D; Wang J; Li Y
    J Med Imaging Radiat Oncol; 2012 Apr; 56(2):136-42. PubMed ID: 22498184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of PET in medullary thyroid carcinoma.
    Rufini V; Treglia G; Perotti G; Leccisotti L; Calcagni ML; Rubello D
    Minerva Endocrinol; 2008 Jun; 33(2):67-73. PubMed ID: 18388854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma.
    Beuthien-Baumann B; Strumpf A; Zessin J; Bredow J; Kotzerke J
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1604-9. PubMed ID: 17435996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma.
    Luster M; Karges W; Zeich K; Pauls S; Verburg FA; Dralle H; Glatting G; Buck AK; Solbach C; Neumaier B; Reske SN; Mottaghy FM
    Thyroid; 2010 May; 20(5):527-33. PubMed ID: 20450432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy.
    Oudoux A; Salaun PY; Bournaud C; Campion L; Ansquer C; Rousseau C; Bardet S; Borson-Chazot F; Vuillez JP; Murat A; Mirallié E; Barbet J; Goldenberg DM; Chatal JF; Kraeber-Bodéré F
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4590-7. PubMed ID: 17878252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study.
    Rubello D; Rampin L; Nanni C; Banti E; Ferdeghini M; Fanti S; Al-Nahhas A; Gross MD
    Eur J Surg Oncol; 2008 May; 34(5):581-6. PubMed ID: 17892923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study.
    Musholt TJ; Musholt PB; Dehdashti F; Moley JF
    Surgery; 1997 Dec; 122(6):1049-60; discussion 1060-1. PubMed ID: 9426419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study.
    Diehl M; Risse JH; Brandt-Mainz K; Dietlein M; Bohuslavizki KH; Matheja P; Lange H; Bredow J; Körber C; Grünwald F
    Eur J Nucl Med; 2001 Nov; 28(11):1671-6. PubMed ID: 11702109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer.
    Faggiano A; Grimaldi F; Pezzullo L; Chiofalo MG; Caracò C; Mozzillo N; Angeletti G; Santeusanio F; Lombardi G; Colao A; Avenia N; Ferolla P
    Endocr Relat Cancer; 2009 Mar; 16(1):225-31. PubMed ID: 19004986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG and non-18F-FDG PET radiopharmaceuticals.
    Wong KK; Laird AM; Moubayed A; Chondrogiannis S; Marzola MC; Evangelista L; Gross MD; Rubello D
    Nucl Med Commun; 2012 Jul; 33(7):679-88. PubMed ID: 22422100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma.
    Bogsrud TV; Karantanis D; Nathan MA; Mullan BP; Wiseman GA; Kasperbauer JL; Reading CC; Björo T; Hay ID; Lowe VJ
    Mol Imaging Biol; 2010 Oct; 12(5):547-53. PubMed ID: 19949985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast metastasis by medullary thyroid carcinoma detected by FDG positron emission tomography.
    Nofech-Mozes S; Mackenzie R; Kahn HJ; Ehrlich L; Raphael SJ
    Ann Diagn Pathol; 2008 Feb; 12(1):67-71. PubMed ID: 18164420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.